INTRODUCTION
Tracheal stenosis is a congenital or secondary disease caused by infection, cancer, trauma, or endometrial tuberculosis. Clinical manifestations of tracheal stenosis include cough, expectoration, dyspnea and respiratory failure. Stent implantation quickly relieves the dyspnea and improves the quality of patient's life [1] . Under some conditions, stent (a small mesh tube that is used to treat narrow or weak arteries) placement is absolutely necessary, since surgery is contra-indicated [2] . Unfortunately, intratracheal stent can damage the airway mucosa, and cause excessive proliferation of fibrous tissue. These lead to stent restenosis, which seriously affects the clinical efficacy of stent implantation [3] . In recent years, clinically-applied drug-eluting stent (DES) has been used in a wide range of patients with cardiopathy, gastroenteropathy or urologic diseases [4, 5] . It has also been shown that DES significantly reduces incidence of stent restenosis when compared with bare-metal stent [6] . However research on applications of DES in tracheal stenosis treatment is still limited.
Sirolimus is a new immunosuppressant drug. Klugherz et al [7] found that sirolimus inhibits DNA synthesis in vascular smooth muscle cells and platelet-derived growth factor (PDGF)-induced migration of cells, as well as proliferation and migration of smooth muscle cell and granuloma growth. Thus, sirolimus-coated stents have been widely used in the prevention of restenosis in patients with coronary heart disease needing coronary stent implantation [5] . However studies on the application of sirolimuseluting stent in intratracheal restenosis are limited. A drug-coated stent consists of baremetal stent, drugs, and a carrier. PLGA is a degradable, organic functional polymer approved by the US Food and Drug Administration (FDA). It can be used in the manufacture of medical devices, and has been applied in rat or rabbit model research on biological coating materials [8, 9] . Sirolimus is a novel anti-tumor and immunosuppressive agent, which can suppress the growth of granuloma by inhibiting local inflammatory cascade [7, 8, 10, 11] . Charytan et al confirmed that m-TOR inhibitor sirolimuscoated stent was better than bare-metal stent in the inhibition of coronary stent restenosis. However, the effects of sirolimus-coated stent or bare-metal stent on tracheal restenosis are still unknown.
In this present study, we investigated the preparation of sirolimus-coated trachea stent and its pharmacokinetics in vitro. The duration of drug release, drug loading, optimum concentration ratio of drug and PLGA were determined, with a view to determining efficacy and safety of sirolimus-coated stent in the treatment of tracheal stenosis in vivo.
EXPERIMENTAL Preparation of sirolimus-coated trachea stents
Bare nitinol stent was soaked in dichloromethane (Tianjin Tianli Chemicals Ltd) for 2 h and then washed with distilled water before it was placed in ventilation cabinet for 2 h to remove residual water. The stent was further washed with distilled water in ultrasonic cleaner for 20 min to remove surface impurities, and dried in the oven at r 50 
Scanning electronic microscopy (SEM) of coated stent
The morphology, thickness and drug pellicles of the prepared stent surface were observed with SEM (× 100). The coated stent was then put in phosphate buffered saline for 42 days, and changes in morphology and structure of the stent surface were observed with SEM.
Evaluation of pharmacokinetics of DES in vitro
The prepared stents were separately placed in glass tubes; 10 mL phosphate buffer (0.15mol/L, pH 7.4) were added as dissolution medium and all tubes were incubated at 37 o C in a shaker box stirred at 75 rev/min continuously for 48 h. The dissolution medium was then collected for determination of drug concentration, and was replaced with fresh phosphate buffer. This process was repeated consecutively for six weeks. Finally, the stent was put in 10 mL dichloromethane solution overnight at room temperature. The dichloromethane was then transferred into a vial to analyze its drug residue content.
Concentrations of sirolimus in dissolution medium were determined every two days by enzyme amplification immunoassay for a consecutive period of 42 days [13] . Drug release, cumulative release and residual amount of drugs in DES were determined. Total drug loading and drug release time from DES were calculated and the pharmacokinetic profiles of stent and optimal coated ratio of drug and PLGA were also evaluated.
Statistical analysis
Data were analysis using descriptive statistics (percentages, mean ± standard deviation) as appropriate and one-way analysis of variance (ANOVA) was used for data comparison. P < 0.05 was considered significant.
RESULTS

Morphological characteristics of drug-eluting stents
As shown in Figure 1a , drug pellicles were smoothly attached to the stent after the drugcoated stent preparation procedures. After soaking in phosphate buffer for 42 days, the coated structure of stent surface changed with the degradation of PLGA, as was evident from the numerous holes on its surface (Figure 1b ). (Table 1) . Maximum drug loading of stent was obtained at sirolimus/PLGA ratio of 1:10. Stent drug loading did not increase with further increases in sirolimus/PLGA ratios.
In vitro pharmacokinetics of sirolimus release
The release profiles of sirolimus in DES over time are shown in Figure 2 . From Figure 2 , it can be seen that about 02-0.5 mcg of the drug was released in the first 5 days (in which case there was slow release of drug during that period) and rapid release occurred about the 5 th -9 th day (during which about 60 %) of the drug was released) and thereafter a slower sustained release occurred.
About 50 % stent-carried drug was released in first two weeks; there was nearly 70 % drug release in 28 days; while about 80 % was released in 42 days (Figure 3 ). 
DISCUSSION
In this study, a sustained and effective role of sirolimus-coated stent on drug release has been found. Zhu et al [14] demonstrated for the first time that drug-eluting stent prepared from mitomycin C-coated tracheal stent is an effective and most promising treatment for stent restenosis. The drugs in coated stent can be released directly and continuously to a specific site without interacting with other tissues. This reduces incidence of restenosis. In this study, we developed the sirolimus-coated stent with favorable surface morphology and good drug release, which was evaluated as safe, effective in the treatment of tracheal stenosis in vivo. It has been demonstrated that the performance of DES depends on drug loading, drug release rate and duration. Drug/coating ratio plays an important role in this process [15] . The results of our study suggest that the best ratio for sirolimus : PLGA coating is 1:10, which enables the stent carry the highest amount of drug. Drug loading did not increase with increase the concentration of sirolimus in solution, suggesting a saturation effect. Kong et al [16] reported that the optimal paclitaxel : stent coating ratio was 1:20, while Yin-Kai Chao et al [17] determined that the optimal cisplatin : coating ratio was 1:9. These differences may be related to differences in solubilities of drugs.
Soaking is a relatively simple and important method for preparing coated stents [18] . Drug pellicles were attached to the newly prepared stent uniformly and smoothly. However, after soaking in phosphate buffer for 42 days, many holes were observed in the surface of drugcoated stent with the degradation of PLGA, indicating that sirolimus might diffuse through these gaps or holes.
The drug release curve of drug-coated stents is uncertain [19] . In sirolimus-eluting stents, drug release lasted for more than 42 days while about 50 % stent carried drugs was released in first two weeks. Although different drug : coating ratios had different drug concentrations, the processes of drug release were roughly the same in vitro. Therefore, suitable coating materials and appropriate drug : coating ratios are key factors for maximizing the effects of DES.
Previous studies suggested that the mechanisms of in vitro drug release in DES were mainly based on drug diffusion and degradation of the stent polymer [20, 21] . Pires et al [22] found that there was a quick release period and a subsequent slow release period of drugs from DES in vitro. As shown in present study, the sirolimus dissolved rapidly and the stent polymer was eroded in the quick release period. Thereafter, the drug release profile entered a slow phase until the end based on gradual diffusion through porous regions when the polymer materials were degraded or flaked.
The profiles of prepared DES need to be further confirmed in vivo, even though some researchers have suggested that sirolimus metabolism in vitro is similar to that in vivo [23] Drug release process in vitro may be actually different from that in vivo due to changes in environment and acid-base metabolism [23, 24] .
CONCLUSION
We have successfully produced a trachea sirolimus-coated stents and evaluated their drug release pharmacokinetics in vitro. The results show that the DES has a good surface morphology, as well as sustained and effective drug release characteristics.
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